glp 1 nestle GLP‑1 Disruption, Nestlé's Strategy Shift and Reformulation Pressure Nestlé's GLP-1 push takes in
Description
Nausea is the most common, affecting roughly 40% of patients in clinical trials
Circulation 124 (21), 23382349
[DOI] [PubMed] [Google Scholar] 159.Snchez-Garrido M.A., Brandt S.J., Clemmensen C., Mller T.D., DiMarchi R.D., Tschp M.H
Statements Data availability statement The original contributions presented in the study are included in the article/ Supplementary Materials , further inquiries can be directed to the corresponding author/s
Both medications work
These include producing short-chain fatty acids (SCFAs) such as butyrate and propionate, which can stimulate L-cell activity and enhance GLP-1 secretion
